Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Hema.to GmbH

hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system. *

 

Period Start 2021-10-19 established
Product Industry single cell analysis
Person Person Miermans, Karsten (Hema.to 202306 CEO + Co-Founder)
     
Region Region München (Munich)
  Country Germany
  Street 22 Ainmillerstr.
  City 80801 München
    Address record changed: 2023-07-03
     
Basic data Employees n. a.
     
    * Document for »About Section«: High-Tech Gründerfonds Management GmbH. (6/26/23). "Press Release: Hema.to Raises €3.6M to Bring Precision Diagnostics to Immune Medicine Using AI-assisted Analysis of Single-cell Blood Data".
     
   
Record changed: 2023-12-30

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Hema.to GmbH


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top